Chengdu HUITAI Biomedicine is a clinical-stage biotech company focused on developing pan anti-fibrotic peptides through novel TGF-β technology. Unlike conventional TGF-β inhibitors that target integrins or TGF-β directly, HUITAI's lead asset, HTPEP-001, selectively antagonizes the interaction between TSP-1 and CD36 to block TGF-β1 activation.

This mechanism preserves antifibrotic efficacy while markedly expanding the therapeutic safety window.

Inhaled HTPEP-001 has demonstrated significant efficacy in reducing active TGF-β1 and alleviating lung fibrosis in preclinical animal models, with a safety margin exceeding 50-fold. The Phase I clinical trial confirmed its excellent safety and tolerability profile in humans, positioning inhaled HTPEP-001 as a promising therapeutic candidate for PF-ILD and IPF treatment.